On September 24, 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, reported that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma ("PDAC") have been selected for a late-breaking Proffered Paper oral presentation at the European Society for Medical Oncology ("ESMO") Congress 2026, being held October 23–27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to share the complete AMPLIFY-7P results, including new late-breaking analyses, with the global oncology community at ESMO (Free ESMO Whitepaper) Congress 2026," said Robert Connelly, President and Chief Executive Officer of Elicio. "These findings deepen our understanding of ELI-002 7P’s clinical and biological activity and provide important direction as we refine the development strategy for a potential Phase 3 study in adjuvant pancreatic cancer."
Proffered Paper Presentation Details
Abstract Number: LBA83
Title: Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study
Presenter: Eileen M. O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
Date and Time: October 23, 2026, 13:30-15:00 PM, CEST / 7.30-9 AM EST
Location: Almeria Auditorium- Hall 9
The late-breaking abstract will be available via the ESMO (Free ESMO Whitepaper) Congress 2026 website beginning at 00:05 CEST on October 23, 2026, the day of the presentation. Subject to presenter permission, a webcast of the session will be available on ESMO (Free ESMO Whitepaper) Congress 2026 Virtual Platform within 12 hours following the session.
About the AMPLIFY-7P Phase 2 Study
AMPLIFY-7P is a randomized Phase 2 study evaluating ELI-002 7P versus observation in patients with mKRAS-driven PDAC following completion of standard therapy. The study enrolled 144 patients across 24 U.S. clinical sites.
While the study did not meet its pre-specified primary disease-free survival ("DFS") endpoint in the intent-to-treat population, subsequent analyses have provided important insights into the clinical and biological activity of ELI-002 7P and informed the Company’s continued evaluation of the program.
At ESMO (Free ESMO Whitepaper) Congress 2026, Elicio will present new pre-specified analyses from AMPLIFY-7P that provide additional insights into the potential clinical benefit of ELI-002 7P and are expected to further inform the Company’s refined Phase 3 development strategy in adjuvant pancreatic cancer.
About ELI-002
Elicio’s lead product candidate, ELI-002, is a structurally novel investigational Amphiphile ("AMP") cancer immunotherapy that targets cancers driven by mutations in the KRAS gene, a prevalent driver of many human cancers. ELI-002 is comprised of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant, and is available as an off-the-shelf subcutaneous administration.
ELI-002 7P, the seven-peptide formulation, was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-driven pancreatic cancer. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present across multiple solid tumors.
(Press release, Elicio Therapeutics, SEP 24, 2026, View Source [SID1234671054])